{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:08:20Z","timestamp":1762250900842,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81761128016","81872782"],"award-info":[{"award-number":["81761128016","81872782"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","award":["2016-I2M-3-012","2016-I2M-3-022"],"award-info":[{"award-number":["2016-I2M-3-012","2016-I2M-3-022"]}],"id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.imlet.2019.12.010","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T12:08:54Z","timestamp":1577794134000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity"],"prefix":"10.1016","volume":"220","author":[{"given":"Qingming","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2019.12.010_bib0005","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri1842","article-title":"Adoptive immunotherapy for cancer: building on success","volume":"6","author":"Gattinoni","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2019.12.010_bib0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2141.1994.tb08297.x","article-title":"Propagation of large numbers of T cells with natural killer cell markers","volume":"87","author":"Schmidt-Wolf","year":"1994","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nri3174","article-title":"Targeting natural killer cells and natural killer T cells in cancer","volume":"12","author":"Vivier","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0025","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2019.12.010_bib0030","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S0140-6736(00)02654-4","article-title":"Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial","volume":"356","author":"Takayama","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.imlet.2019.12.010_bib0035","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2002-06-1751","article-title":"Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging","volume":"101","author":"Edinger","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.12.010_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1479-5876-11-83","article-title":"Cytokine-induced killer cells promote antitumor immunity","volume":"11","author":"Jiang","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.imlet.2019.12.010_bib0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/14712598.2012.675323","article-title":"Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors","volume":"12","author":"Mesiano","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.imlet.2019.12.010_bib0050","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hon.886","article-title":"Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial","volume":"27","author":"Olioso","year":"2009","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00432-010-0887-7","article-title":"Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)","volume":"137","author":"Hontscha","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ajh.21253","article-title":"Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission","volume":"83","author":"Stone","year":"2008","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0065","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14653240701589221","article-title":"Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer","volume":"9","author":"Dohnal","year":"2007","journal-title":"Cytotherapy"},{"key":"10.1016\/j.imlet.2019.12.010_bib0070","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/14712598.2012.676037","article-title":"CIK cells--current status, clinical perspectives and future prospects--the good news","volume":"12","author":"Hui","year":"2012","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.imlet.2019.12.010_bib0075","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.tibtech.2013.08.007","article-title":"A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications","volume":"31","author":"Byrne","year":"2013","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0080","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.163.3.1246","article-title":"Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing","volume":"163","author":"Zeidler","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0085","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.4049\/jimmunol.1101760","article-title":"Retargeting of human regulatory T cells by single-chain bispecific antibodies","volume":"188","author":"Koristka","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0090","first-page":"276","article-title":"Bispecific antibodies for cancer therapy","volume":"12","author":"Chames","year":"2009","journal-title":"Curr. Opin. Drug Discov. Devel."},{"key":"10.1016\/j.imlet.2019.12.010_bib0095","first-page":"22","article-title":"BiTE: Teaching antibodies to engage T-cells for cancer therapy","volume":"11","author":"Baeuerle","year":"2009","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.imlet.2019.12.010_bib0100","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"Loffler","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.12.010_bib0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14653249.2011.613931","article-title":"The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells","volume":"14","author":"Rettinger","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.imlet.2019.12.010_bib0110","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.7314\/APJCP.2013.14.10.5825","article-title":"Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways","volume":"14","author":"Rajbhandary","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.imlet.2019.12.010_bib0115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/CJI.0000000000000001","article-title":"IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35","volume":"36","author":"Tao","year":"2013","journal-title":"J. Immunother."},{"key":"10.1016\/j.imlet.2019.12.010_bib0120","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1158\/0008-5472.CAN-12-2893","article-title":"Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy","volume":"73","author":"Lim","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.imlet.2019.12.010_bib0125","doi-asserted-by":"crossref","first-page":"11075","DOI":"10.1038\/s41598-017-09259-1","article-title":"Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imlet.2019.12.010_bib0130","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00262-014-1614-z","article-title":"Immunophenotypic and functional characterization of ex vivo expanded natural killer cells for clinical use in acute lymphoblastic leukemia patients","volume":"64","author":"Peragine","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imlet.2019.12.010_bib0135","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00262-018-2211-3","article-title":"Ex vivo expanded tumour-infiltrating lymphocytes from ovarian cancer patients release anti-tumour cytokines in response to autologous primary ovarian cancer cells","volume":"67","author":"Owens","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imlet.2019.12.010_bib0140","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1182\/blood.V80.9.2221.2221","article-title":"Role of monocytes in the expansion of human activated natural killer cells","volume":"80","author":"Miller","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.12.010_bib0145","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0150","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3324\/haematol.2012.082248","article-title":"Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells","volume":"98","author":"Wong","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2019.12.010_bib0155","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.12.010_bib0160","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/CJI.0b013e318255ada3","article-title":"Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells","volume":"35","author":"Lin","year":"2012","journal-title":"J. Immunother."},{"key":"10.1016\/j.imlet.2019.12.010_bib0165","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10875-007-9076-0","article-title":"CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients","volume":"27","author":"Li","year":"2007","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0170","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2009-03-208181","article-title":"Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia","volume":"114","author":"Zhou","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.12.010_bib0175","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood-2008-01-135319","article-title":"Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines","volume":"112","author":"Morse","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.12.010_bib0180","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00262-010-0866-5","article-title":"Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy","volume":"59","author":"Coe","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imlet.2019.12.010_bib0185","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.imlet.2019.12.010_bib0190","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0195","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.imlet.2016.11.009","article-title":"Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4(+)CD25(bri) regulatory T cells","volume":"181","author":"Zhao","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.imlet.2019.12.010_bib0200","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2019.12.010_bib0205","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.imlet.2019.12.010_bib0210","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.4049\/jimmunol.1302290","article-title":"Tim-3 directly enhances CD8 T cell responses to acute Listeria monocytogenes infection","volume":"192","author":"Gorman","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.imlet.2019.12.010_bib0215","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1182\/blood-2011-11-392951","article-title":"Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity","volume":"119","author":"Ndhlovu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2019.12.010_bib0220","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2011-06-360321","article-title":"Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9","volume":"119","author":"Gleason","year":"2012","journal-title":"Blood"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247819304122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247819304122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:03:55Z","timestamp":1762250635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247819304122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":44,"alternative-id":["S0165247819304122"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2019.12.010","relation":{},"ISSN":["0165-2478"],"issn-type":[{"type":"print","value":"0165-2478"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibody activated T cells: A newly developed T cells with enhanced proliferation ability and cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2019.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}